Increased Levels of Endotoxin Core Antibodies and Decreased Levels of sCD 14 Indicate Chronic Endotoxemia in Coronary Artery Disease (CURES-127)
|Vivekanandhan Aravindhan1*, Viswanathan Mohan2, Haridoss Madhumitha1, Srinivasan Valarmathi3 and Subash Babu4|
|1AU-KBC Research Centre, MIT Campus of Anna University, Chennai, India|
|2Madras Diabetes Research Foundation & Dr. Mohan’s Diabetes Specialties Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control, International Diabetes Federation (IDF) Centre for Education Chennai, India|
|3Dept of Epidemiology, Tamil Nadu Dr.MGR Medical University, Guindy, Chennai, India|
|4National Institutes of Health-International Center for Excellence in Research, National Institute for Research in Tuberculosis, Chennai, India|
|Corresponding Author :||Vivekanandhan Aravindhan, PhD
AU-KBC, MIT Campus of Anna University
Chromepet, Chennai-600 044, India
Tel: 044 2223 2711
Fax: 044 2223 1034
E-mail: [email protected]
|Received June 01, 2013; Accepted July 25, 2013; Published July 27, 2013|
|Citation: Aravindhan V, Mohan V, Madhumitha H, Valarmathi S, Babu S (2013) Increased Levels of Endotoxin Core Antibodies and Decreased Levels of sCD 14 Indicate Chronic Endotoxemia in Coronary Artery Disease (CURES-127). J Clin Exp Cardiolog 4:264. doi:10.4172/2155-9880.1000264|
|Copyright: © 2013 Aravindhan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Introduction: Endotoxin is hypothesized to play an important role in chronic inflammation associated with coronary artery disease (CAD). The activity of the endotoxin is determined by the relative levels of endotoxin core antibodies (EndoCab), LPS binding protein (LBP) and soluble CD14 (sCD14). Towards this end, we estimated EndoCab, LBP and sCD14 levels in subjects with CAD and correlated them with clinical parameters, serum hormones and cytokine levels.
Methods: The study subjects were recruited from Chennai Urban Rural Epidemiology Study (CURES). Age and gender matched subjects with (n=46) and without (n=45) CAD were selected from Phase III of the study. The levels of serum lipopolysaccharide (LPS), EndoCab and its translocation markers (sCD14 and LBP) along with insulin, glucagon, adiponectin and leptin and pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β were measured by immuno-assays.
Results: Quartile analysis showed significantly higher percentage of CAD subjects in the highest quartile of EndoCab (>26.6 EMU/ml) (CAD-24% Vs Controls 0%) and LPS (>65.05 EU/ml) (CAD-21% vs. Controls 4%), while a reverse trend was seen for sCD14 (>2198398.7 ng/ml) (CAD-1% vs. Control-24%) (p<0.01). LBP levels were not statistically different between the groups. While EndoCab levels showed positive association with LPS, LBP, sCD14, hsCRP, HOMA-IR and glucagon, sCD14 showed a negative association with most of these markers. Significant increase in the levels of pro inflammatory cytokines TNFα, IL-6 and IL-1β, was also observed in the CAD group when compared to the control.
Conclusions: Significantly elevated levels of EndoCab and decreased levels of sCD14 indicate chronic endotoxin exposure in CAD subjects.